HIV Clinical Trial
Official title:
HIV/STI Prevention Among Black Adolescents With Mental Illnesses
Verified date | November 2017 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite advances in HIV/sexually transmitted infection (STI) prevention, Black youth account
for the largest number of new HIV infections among heterosexual youth. Having a mental
illness contributes to HIV/STI risk among heterosexually active Black youth, as some use sex
as a means to manage psychological distress, regulate emotions and receive validation or
acceptance. Current intervention models focus on cognitive-behavioral strategies to reduce
risk among adolescents; however, these approaches in isolation do not address the
psychopathology that further potentiates risk behaviors among adolescents with mental
illnesses. This randomized controlled trial evaluated the effects of "Project GOLD", a
theoretically-driven, gender and culturally relevant, developmentally and psychologically
appropriate HIV/STI risk reduction intervention on the sexual behaviors of Black male and
female adolescents in Philadelphia (aged 14-17). In addition to evidence-based HIV/STI
preventions strategies (e.g., role playing), Project GOLD includes unique emotion regulation
content to address the relationship between psychological distress and HIV/STI risk
behaviors.
The research team approached and screened 704 adolescents. Eighty-two participated in the
elicitation research activities (e.g., focus groups, intervention dress rehearsal). Another
173 underwent a structured demographic and mental health diagnostic interview to determine
RCT eligibility. Project GOLD was then tested with 108 Black youth in comparison to a general
health promotion control condition (intervention n = 52; control n = 56). Youth who were not
in psychiatric treatment were also included, as the investigators hypothesized that they
would also benefit from the targeted psychoeducational content; post-hoc analyses examined
differences in the intervention effects based on whether or not youth were in psychiatric
treatment. The intervention had high feasibility and acceptability. These findings underscore
the need to encourage HIV/STI testing and risk reduction efforts among Black youth, including
those with mental illnesses.
Status | Completed |
Enrollment | 108 |
Est. completion date | December 31, 2016 |
Est. primary completion date | December 22, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 14 Years to 17 Years |
Eligibility |
Inclusion Criteria: - 14 to 17 years old - Self-identify as Black (inclusive of African American, Caribbean-American, etc.) - Have ever had vaginal sex - Able to speak, read and write in the English language - Able to provide signed informed consent/assent - Plan to be in the Philadelphia area for the next 12 months. Exclusion Criteria: - Diagnosis of a psychotic disorder (i.e. Schizophrenia) or a disorder with psychotic features (ascertained by the MINI) - Cognitive deficit that would impair ability to complete study procedures - Actively suicidal (ascertained through the Columbia-Suicide Severity Rating Scale [C-SSRS]) or requiring hospitalization - Unstable contact information (i.e. homeless or no permanent address, or no land line or mobile phone) Participants were not excluded for concurrent use of herbal remedies, mineral supplements, or psychopharmacologic therapies, however these factors will be controlled for in the data analyses. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania | Centers for Disease Control and Prevention, National Institute of Mental Health (NIMH) |
United States,
Brawner BM, Jemmott LS, Wingood G, Reason J, Mack N. HIV/STI Prevention Among Heterosexually Active Black Adolescents With Mental Illnesses: Focus Group Findings for Intervention Development. J Assoc Nurses AIDS Care. 2017 Sep 28. pii: S1055-3290(17)30236-4. doi: 10.1016/j.jana.2017.09.008. [Epub ahead of print] — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline consistent condom use at 12 months | This dichotomous variable was defined by the comparison of the number of protected intercourse acts and the number of intercourse acts. Participants who report at least one intercourse act and whose number of reported protected acts equals their number of acts use condoms during 100% of intercourse acts and will be defined as practicing consistent condom use. Participants who report at least one intercourse act and whose reported number of protected acts is less than their number of acts will be coded as not practicing consistent condom use. | 12 months | |
Secondary | Change from baseline number of sexual partners at 12 months | A continuous variable was calculated in response to questions about the number of sexual partners participants had in the past 12-months. | 12 months | |
Secondary | Change from baseline laboratory confirmed STIs at 12 months | Diagnosis of Chlamydia trachomatis (CT) and Neisseria gonorrhea (GC) was made based on DNA amplification tests on urine specimens at baseline and follow-up. Participants provided an on-site first-void urine specimen of approximately 15 to 20 cc. Dichotomized as positive STI result yes/no. | 12 months | |
Secondary | Change from baseline HIV Diagnosis at 12 months | Diagnosis of HIV was made based by laboratory confirmation following a positive OraQuick Advance Rapid HIV-1/2 antibody test at baseline and follow-up. This rapid HIV antibody tests detects antibodies to HIV-1 and HIV-2 within 20 minutes (Oraquick; Orasure Technologies, Inc.). Saliva was swabbed between the teeth and upper and lower gum by a certified HIV tester and counselor from the partner ASO. Dichotomized as HIV positive yes/no. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |